Table 1.
Trials characteristics.
| Characteristics | N (%) |
|---|---|
| Interventions | |
| Caffeine | 1 (6.7) |
| Chlorogenic acid | 1 (6.7) |
| Ginger | 1 (6.7) |
| Omega-3 fatty acids | 3 (20.0) |
| Phosphatidylcholine | 1 (6.7) |
| Trigonella Foenum-graecum seed extract | 1 (6.7) |
| Vitamin C | 1 (6.7) |
| Vitamin D | 4 (26.7) |
| Vitamin E | 2 (13.3) |
| Phases | |
| Phase 3 | 9 (75.0) |
| Phase 4 | 3 (25.0) |
| Allocation | |
| Randomized | 12 (100.0) |
| Intervention model | |
| Parallel assignment | 11 (91.7) |
| Single group assignment | 1 (8.3) |
| Masking | |
| Open label | 1 (8.3) |
| Single (investigator) | 1 (8.3) |
| Double (participant, care provider) | 1 (8.3) |
| Triple (participant, care provider, investigator) | 2 (16.7) |
| Quadruple (participant, care provider, investigator, outcomes assessor) | 7 (58.3) |
| Locations | |
| Croatia | 1 (8.3) |
| Egypt | 1 (8.3) |
| Iran | 3 (25.0) |
| Italy | 2 (16.7) |
| Korea | 1 (8.3) |
| United Kingdom | 2 (16.7) |
| United States | 2 (16.7) |
| Publication status | |
| Published | 6 (50.0) |
| Not published | 6 (50.0) |